Alex Abou-Chebl1, Sharon D Yeatts2, Bernard Yan2, Kevin Cockroft2, Mayank Goyal2, Tudor Jovin2, Pooja Khatri2, Phillip Meyers2, Judith Spilker2, Rebecca Sugg2, Katja E Wartenberg2, Tom Tomsick2, Joe Broderick2, Michael D Hill2. 1. From Baptist Neuroscience Associates, Baptist Health, Louisville, KY (A.A.-C.); Department of Public Health Sciences, Medical University of South Carolina, Charleston (S.D.Y.); Department of Neurology, Royal Melbourne Hospital, Parkville, Australia (B.Y.); Departments of Neurosurgery, Radiology, and Public Health Sciences, Penn State Hershey, PA (K.C.); Departments of Radiology and Clinical Neurosciences, Foothills Medical Centre, Calgary, AB, Canada (M.G.); Department of Neurology, University of Pittsburgh Medical Center, PA (T.J.); Department of Neurology (P.K., J.S., J.B.) and Department of Radiology (T.T.), University of Cincinnati, OH; Departments of Radiology and Neurological Surgery, Columbia University, New York, NY (P.M.); Department of Neurology, University of Mississippi, Jackson (R.S.); Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle, Germany (K.E.W.); and Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada (M.D.H.). achebl@yahoo.com. 2. From Baptist Neuroscience Associates, Baptist Health, Louisville, KY (A.A.-C.); Department of Public Health Sciences, Medical University of South Carolina, Charleston (S.D.Y.); Department of Neurology, Royal Melbourne Hospital, Parkville, Australia (B.Y.); Departments of Neurosurgery, Radiology, and Public Health Sciences, Penn State Hershey, PA (K.C.); Departments of Radiology and Clinical Neurosciences, Foothills Medical Centre, Calgary, AB, Canada (M.G.); Department of Neurology, University of Pittsburgh Medical Center, PA (T.J.); Department of Neurology (P.K., J.S., J.B.) and Department of Radiology (T.T.), University of Cincinnati, OH; Departments of Radiology and Neurological Surgery, Columbia University, New York, NY (P.M.); Department of Neurology, University of Mississippi, Jackson (R.S.); Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle, Germany (K.E.W.); and Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada (M.D.H.).
Abstract
BACKGROUND AND PURPOSE:General anesthesia (GA) for endovascular therapy (EVT) of acute ischemic stroke may be associated with worse outcomes. METHODS: The Interventional Management of Stroke III trial randomized patients within 3 hours of acute ischemic stroke onset to intravenous tissue-type plasminogen activator±EVT. GA use within 7 hours of stroke onset was recorded per protocol. Good outcome was defined as 90-day modified Rankin Scale ≤2. A multivariable analysis adjusting for dichotomized National Institutes of Health Stroke Scale (NIHSS; 8-19 versus ≥20), age, and time from onset to groin puncture was performed. RESULTS:Four hundred thirty-four patients were randomized to EVT, 269 (62%) were treated under local anesthesia and 147 (33.9%) under GA; 18 (4%) were undetermined. The 2 groups were comparable except for median baseline NIHSS (16 local anesthesia versus 18 GA; P<0.0001). The GA group was less likely to achieve a good outcome (adjusted relative risk, 0.68; confidence interval, 0.52-0.90; P=0.0056) and had increased in-hospital mortality (adjusted relative risk, 2.84; confidence interval, 1.65-4.91; P=0.0002). Those with medically indicated GA had worse outcomes (adjusted relative risk, 0.49; confidence interval, 0.30-0.81; P=0.005) and increased mortality (relative risk, 3.93; confidence interval, 2.18-7.10; P<0.0001) with a trend for higher mortality with routine GA. There was no significant difference in the adjusted risks of subarachnoid hemorrhage (P=0.32) or symptomatic intracerebral hemorrhage (P=0.37). CONCLUSIONS: GA was associated with worse neurological outcomes and increased mortality in the EVT arm; this was primarily true among patients with medical indications for GA. Relative risk estimates, though not statistically significant, suggest reduced risk for subarachnoid hemorrhage and symptomatic intracerebral hemorrhage under local anesthesia. Although the reasons for these associations are not clear, these data support the use of local anesthesia when possible during EVT. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
RCT Entities:
BACKGROUND AND PURPOSE: General anesthesia (GA) for endovascular therapy (EVT) of acute ischemic stroke may be associated with worse outcomes. METHODS: The Interventional Management of Stroke III trial randomized patients within 3 hours of acute ischemic stroke onset to intravenous tissue-type plasminogen activator±EVT. GA use within 7 hours of stroke onset was recorded per protocol. Good outcome was defined as 90-day modified Rankin Scale ≤2. A multivariable analysis adjusting for dichotomized National Institutes of Health Stroke Scale (NIHSS; 8-19 versus ≥20), age, and time from onset to groin puncture was performed. RESULTS: Four hundred thirty-four patients were randomized to EVT, 269 (62%) were treated under local anesthesia and 147 (33.9%) under GA; 18 (4%) were undetermined. The 2 groups were comparable except for median baseline NIHSS (16 local anesthesia versus 18 GA; P<0.0001). The GA group was less likely to achieve a good outcome (adjusted relative risk, 0.68; confidence interval, 0.52-0.90; P=0.0056) and had increased in-hospital mortality (adjusted relative risk, 2.84; confidence interval, 1.65-4.91; P=0.0002). Those with medically indicated GA had worse outcomes (adjusted relative risk, 0.49; confidence interval, 0.30-0.81; P=0.005) and increased mortality (relative risk, 3.93; confidence interval, 2.18-7.10; P<0.0001) with a trend for higher mortality with routine GA. There was no significant difference in the adjusted risks of subarachnoid hemorrhage (P=0.32) or symptomatic intracerebral hemorrhage (P=0.37). CONCLUSIONS: GA was associated with worse neurological outcomes and increased mortality in the EVT arm; this was primarily true among patients with medical indications for GA. Relative risk estimates, though not statistically significant, suggest reduced risk for subarachnoid hemorrhage and symptomatic intracerebral hemorrhage under local anesthesia. Although the reasons for these associations are not clear, these data support the use of local anesthesia when possible during EVT. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00359424.
Authors: Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks Journal: Stroke Date: 2007-04-12 Impact factor: 7.914
Authors: Albert J Yoo; Javier Romero; Reza Hakimelahi; Raul G Nogueira; James D Rabinov; Johnny C Pryor; R Gilberto González; Joshua A Hirsch; Pamela W Schaefer Journal: BMC Neurol Date: 2010-04-23 Impact factor: 2.474
Authors: Pooja Khatri; Michael D Hill; Yuko Y Palesch; Judith Spilker; Edward C Jauch; Janice A Carrozzella; Andrew M Demchuk; Renee' Martin; Patrick Mauldin; Catherine Dillon; Karla J Ryckborst; Scott Janis; Thomas A Tomsick; Joseph P Broderick Journal: Int J Stroke Date: 2008-05 Impact factor: 5.266
Authors: Joseph P Broderick; Yuko Y Palesch; Andrew M Demchuk; Sharon D Yeatts; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Frank L Silver; Rüdiger von Kummer; Carlos A Molina; Bart M Demaerschalk; Ronald Budzik; Wayne M Clark; Osama O Zaidat; Tim W Malisch; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Renée H Martin; Lydia D Foster; Thomas A Tomsick Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: N A Vora; R Gupta; A J Thomas; M B Horowitz; A H Tayal; M D Hammer; K Uchino; L R Wechsler; T G Jovin Journal: AJNR Am J Neuroradiol Date: 2007-08 Impact factor: 3.825
Authors: Jens Fiehler; Christophe Cognard; Mauro Gallitelli; Olav Jansen; Adam Kobayashi; Heinrich P Mattle; Keith W Muir; Mikael Mazighi; Karl Schaller; Peter D Schellinger Journal: Eur Stroke J Date: 2016-07-26
Authors: C J Powers; D Dornbos; M Mlynash; D Gulati; M Torbey; S M Nimjee; M G Lansberg; G W Albers; M P Marks Journal: AJNR Am J Neuroradiol Date: 2019-05-09 Impact factor: 3.825
Authors: F Flottmann; H Leischner; G Broocks; T D Faizy; A Aigner; M Deb-Chatterji; G Thomalla; J Krauel; M Issleib; J Fiehler; C Brekenfeld Journal: AJNR Am J Neuroradiol Date: 2019-12-05 Impact factor: 3.825
Authors: Renato Tosello; Rachel Riera; Giuliano Tosello; Caroline Nb Clezar; Jorge E Amorim; Vladimir Vasconcelos; Benedito B Joao; Ronald Lg Flumignan Journal: Cochrane Database Syst Rev Date: 2022-07-20
Authors: Joseph T Marion; Seyed Mohammad Seyedsaadat; Jeffery J Pasternak; Alejandro A Rabinstein; David F Kallmes; Waleed Brinjikji Journal: Interv Neuroradiol Date: 2020-05-06 Impact factor: 1.610
Authors: Silvia Schönenberger; Pia Löwhagen Hendén; Claus Z Simonsen; Lorenz Uhlmann; Christina Klose; Johannes A R Pfaff; Albert J Yoo; Leif H Sørensen; Peter A Ringleb; Wolfgang Wick; Meinhard Kieser; Markus A Möhlenbruch; Mads Rasmussen; Alexandros Rentzos; Julian Bösel Journal: JAMA Date: 2019-10-01 Impact factor: 56.272
Authors: Min Chen; Dorothea Kronsteiner; Johannes A R Pfaff; Simon Schieber; Martin Bendszus; Meinhard Kieser; Wolfgang Wick; Markus A Möhlenbruch; Peter A Ringleb; Julian Bösel; Silvia Schönenberger Journal: Neurol Res Pract Date: 2021-05-17